GCP
ADMS

GSA Capital Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

GSA Capital Partners’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-105,551
Closed -$557K – 1919
2021
Q2 		$557K Buy
105,551
+84,538
+402% +$438K 0.06% 562
2021
Q1 		$101K Buy
+21,013
New +$110K 0.02% 1002
2020
Q3 		– Sell
-30,484
Closed -$78K – 1454
2020
Q2 		$78K Sell
30,484
-5,902
-16% -$17.3K 0.04% 512
2020
Q1 		$105K Sell
36,386
-30,527
-46% -$137K 0.03% 892
2019
Q4 		$254K Buy
+66,913
New +$320K 0.03% 1141
2018
Q3 		– Sell
-8,200
Closed -$212K – 2007
2018
Q2 		$212K Buy
+8,200
New +$227K 0.01% 1517
2016
Q1 		– Sell
-7,600
Closed -$215K – 1998
2015
Q4 		$215K Sell
7,600
-24,803
-77% -$418K 0.01% 1620
2015
Q3 		$542K Buy
+32,403
New +$737K 0.03% 1083
2015
Q2 		– Sell
-27,654
Closed -$484K – 2262
2015
Q1 		$484K Buy
27,654
+9,428
+52% +$162K 0.02% 1410
2014
Q4 		$317K Buy
18,226
+5,186
+40% +$78.7K 0.02% 1231
2014
Q3 		$243K Buy
+13,040
New +$224K 0.01% 1397

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's ADMS Position: Q3 2021 in Review

GSA Capital Partners sold out of Adamas Pharmaceuticals (ADMS) in Q3 2021, closing a stake of 105,551 shares — an estimated $557K sold.

GSA Capital Partners first reported a position in ADMS in Q3 2014 and held it in 11 quarters. The position peaked at $557K in Q2 2021. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2021.

  • GSA Capital Partners reported no remaining Adamas Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • GSA Capital Partners sold 105,551 Adamas Pharmaceuticals shares in Q3 2021, an estimated $557K.
  • GSA Capital Partners first reported a position in Adamas Pharmaceuticals in Q3 2014 and held it in 11 quarters.
  • GSA Capital Partners's Adamas Pharmaceuticals position peaked at $557K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2021.

Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.